Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 8/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | CRHBP | P24387 | 2/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9509694 | 0.86 | HTT (0.68) | SMN1; SMN2LMNAKMT2AMAPTALDH1A1 | |
| SCHEMBL20302624 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL18549285 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL30311318 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL27976139 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| Bromide SCHEMBL20984828 | 0.83 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL20984568 | 0.83 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL24749990 | 0.82 | HSPB1 (0.54) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL5226315 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL24042269 | 0.82 | MAPT (0.57) | SMN1; SMN2LMNAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007139951-A9 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH PROTOONCOGENE PRODUCTS | SYNTA PHARMACEUTICALS CORP (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007139951-A2 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH PROTOONCOGENE PRODUCTS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| CN-100335461-C | Arylsulfonanilide ureas | TULARIK INC (US) | 2007-09-05 | — | — | CN | disclosed |
| US-7060718-B2 | Arylsulfonanilide ureas | AMGEN INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20030207864-A1 | Arylsulfonanilide ureas | TULARK INC. | 2003-11-06 | — | — | US | disclosed |
| US-6630513-B1 | Capable of lowering plasma cholesterol levels and inhibiting abnormal cell proliferation, such as in cervical adenocarcinoma | TULARIX INC. | 2003-10-07 | — | — | US | disclosed |
| US-6583165-B2 | Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents | TULARIK INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1115701-B1 | ARYLSULFONANILIDE UREAS | TULARIK INC (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1285911-A2 | Arylsulfonanilide ureas | Tularik Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| CN-1319088-A | Arylsulfonylaniline urease | TULARIK INC (US) | 2001-10-24 | — | — | CN | disclosed |
| US-20010027211-A1 | Arylsulfonanilide ureas | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| EP-1115701-A1 | ARYLSULFONANILIDE UREAS | Tularik Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6214880-B1 | LOWERING PLASMA CHOLESTEROL LEVELS AND INHIBITING ABNORMAL CELL PROLIFERATION WITH SAID COMPOUND; TREATMENT OF CANCER, PSORIASIS, VASCULAR RESTENOSIS, INFECTIONS, ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA | TULARIK INC. | 2001-04-10 | — | — | US | disclosed |
| WO-2001012593-A1 | ARYLSULFONANILIDE DERIVATIVES | TULARIK INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-6153585-A | FOR TREATING CANCER, PSORIASIS, VASCULAR RESTENOSIS, INFECTIONS, ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA | TULARIK INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000017159-A1 | ARYLSULFONANILIDE UREAS | TULARIK INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207864-A1 | Arylsulfonanilide ureas | UTS2R, UACA, UMPS | SMN1; SMN2 4664/4885LMNA 3161/4885MEN1 3494/4885 |
| US-20010027211-A1 | Arylsulfonanilide ureas | UTS2R, UACA, UMPS | SMN1; SMN2 4664/4885LMNA 3161/4885MEN1 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.